{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:32:50Z","timestamp":1793046770452,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","semarthritisrheumatism.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.semarthrit.2016.10.009","type":"journal-article","created":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T22:00:42Z","timestamp":1478037642000},"page":"594-600","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":78,"title":["The cost-effectiveness of HLA-B*5801 screening to guide initial urate-lowering therapy for gout in the United States"],"prefix":"10.1016","volume":"46","author":[{"given":"Eric","family":"Jutkowitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Dubreuil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen M.","family":"Kuntz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyon K.","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2016.10.009_bib1","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1002\/acr.21772","article-title":"2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.semarthrit.2016.10.009_bib2","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1136\/ard.40.3.245","article-title":"Acute adverse reactions attributed to allopurinol in hospitalised patients","volume":"40","author":"McInnes","year":"1981","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2016.10.009_bib3","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1002\/art.34488","article-title":"Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol","volume":"64","author":"Stamp","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2016.10.009_bib4","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1002\/acr.21817","article-title":"Severe cutaneous reactions requiring hospitalization in allopurinol initiators: a population\u2010based cohort study","volume":"65","author":"Kim","year":"2013","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.semarthrit.2016.10.009_bib5","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1001\/jamainternmed.2015.3536","article-title":"Allopurinol use and risk of fatal hypersensitivity reactions: a nationwide population-based study in Taiwan","volume":"175","author":"Yang","year":"2015","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.semarthrit.2016.10.009_bib6","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1177\/106002809302700317","article-title":"Allopurinol hypersensitivity syndrome: a review","volume":"27","author":"Arellano","year":"1993","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.semarthrit.2016.10.009_bib7","first-page":"157","article-title":"Risk factors for the development of ocular complications of Stevens\u2013Johnson syndrome and toxic epidermal necrolysis","volume":"145","author":"Gueudry","year":"2009","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.semarthrit.2016.10.009_bib8","series-title":"Management of gout","first-page":"1","author":"Shekelle","year":"2016"},{"key":"10.1016\/j.semarthrit.2016.10.009_bib9","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1111\/1756-185X.12050","article-title":"HLA\u2010B*5801: utility and cost\u2010effectiveness in the Asia\u2013Pacific region","volume":"16","author":"Yeo","year":"2013","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.semarthrit.2016.10.009_bib10","doi-asserted-by":"publisher","first-page":"4134","DOI":"10.1073\/pnas.0409500102","article-title":"HLA-B* 5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol","volume":"102","author":"Hung","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.semarthrit.2016.10.009_bib11","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1097\/FPC.0b013e328330a3b8","article-title":"Strong association between HLA-B*5801 and allopurinol-induced Stevens\u2013Johnson syndrome and toxic epidermal necrolysis in a Thai population","volume":"19","author":"Tassaneeyakul","year":"2009","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.semarthrit.2016.10.009_bib12","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.2217\/pgs.11.131","article-title":"Allopurinol pharmacogenetics: assessment of potential clinical usefulness","volume":"12","author":"Zineh","year":"2011","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.semarthrit.2016.10.009_bib13","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/1471-2350-12-118","article-title":"Association of HLA-B*5801 allele and allopurinol induced stevens johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis","volume":"12","author":"Somkrua","year":"2011","journal-title":"BMC Med Genet"},{"key":"10.1016\/j.semarthrit.2016.10.009_bib14","doi-asserted-by":"publisher","first-page":"D784","DOI":"10.1093\/nar\/gku1166","article-title":"Allele frequency net 2015 update: new features for HLA epitopes, KIR and disease and HLA adverse drug reaction associations","volume":"43","author":"Gonzalez-Galarza","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.semarthrit.2016.10.009_bib15","doi-asserted-by":"publisher","first-page":"617","DOI":"10.7326\/M14-0227","article-title":"Cost-effectiveness of allopurinol and febuxostat for the management of gout","volume":"161","author":"Jutkowitz","year":"2014","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semarthrit.2016.10.009_bib16","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/01.rhu.0000209882.50228.9f","article-title":"Serum urate levels and gout flares: analysis from managed care data","volume":"12","author":"Sarawate","year":"2006","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2016.10.009_bib17","doi-asserted-by":"publisher","first-page":"925","DOI":"10.4065\/81.7.925","article-title":"Gout medication treatment patterns and adherence to standards of care from a managed care perspective","volume":"81","author":"Sarawate","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.semarthrit.2016.10.009_bib18","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1056\/NEJMoa050373","article-title":"Febuxostat compared with allopurinol in patients with hyperuricemia and gout","volume":"353","author":"Becker","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2016.10.009_bib19","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1093\/rheumatology\/ken457","article-title":"Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study","volume":"48","author":"Schumacher","year":"2009","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2016.10.009_bib20","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1002\/art.24209","article-title":"Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28\u2010week, phase III, randomized, double\u2010blind, parallel\u2010group trial","volume":"59","author":"Schumacher","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2016.10.009_bib21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/ar2978","article-title":"The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial","volume":"12","author":"Becker","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2016.10.009_bib23","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.semarthrit.2016.03.014","article-title":"Racial disparities in the risk of Stevens\u2013Johnson syndrome and toxic epidermal necrolysis as urate-lowering drug adverse events in the US","volume":"46","author":"Lu","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2016.10.009_bib24","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1001\/archsurg.142.1.50","article-title":"Cost-utility analysis applied to the treatment of burn patients in a specialized center","volume":"142","author":"S\u00e1nchez","year":"2007","journal-title":"Arch Surg"},{"key":"10.1016\/j.semarthrit.2016.10.009_bib25","doi-asserted-by":"publisher","first-page":"e94294","DOI":"10.1371\/journal.pone.0094294","article-title":"Cost-Effectiveness analysis of HLA-B*5801 testing in preventing allopurinol-induced SJS\/TEN in Thai population","volume":"9","author":"Saokaew","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.semarthrit.2016.10.009_bib26","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1097\/MLR.0b013e318234a04a","article-title":"Comparing EQ-5D scores for comorbid health conditions estimated using 5 different methods","volume":"50","author":"Ara","year":"2012","journal-title":"Med Care"},{"key":"10.1016\/j.semarthrit.2016.10.009_bib27","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1097\/ICO.0b013e3181f7f363","article-title":"The economic burden of dry eye disease in the United States: a decision tree analysis","volume":"30","author":"Yu","year":"2011","journal-title":"Cornea"},{"key":"10.1016\/j.semarthrit.2016.10.009_bib28","doi-asserted-by":"publisher","first-page":"174","DOI":"10.7326\/0003-4819-154-3-201102010-00007","article-title":"High-value, cost-conscious health care: concepts for clinicians to evaluate the benefits, harms, and costs of medical interventions","volume":"154","author":"Owens","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semarthrit.2016.10.009_bib29","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/0002-9343(84)90743-5","article-title":"Severe allopurinol toxicity: description and guidelines for prevention in patients with renal insufficiency","volume":"76","author":"Hande","year":"2003","journal-title":"Am J Med"},{"key":"10.1016\/j.semarthrit.2016.10.009_bib30","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/gim.2014.195","article-title":"An effective strategy to prevent allopurinol-induced hypersensitivity by HLA typing","volume":"17","author":"Jung","year":"2015","journal-title":"Genet Med"},{"key":"10.1016\/j.semarthrit.2016.10.009_bib31","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1002\/acr.22409","article-title":"Cost-effectiveness Analysis of HLA-B5801 genotyping in the treatment of gout patients with chronic renal insufficiency in Korea","volume":"67","author":"Park","year":"2015","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.semarthrit.2016.10.009_bib32","first-page":"125","article-title":"Cost-effectiveness analysis of genotyping for HLA-B*5801and an enhanced safety program in gout patients starting allopurinol in Singapore","volume":"15","author":"Dong","year":"2015","journal-title":"Pharmacogenomics"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017216301147?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017216301147?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,7]],"date-time":"2018-09-07T02:22:49Z","timestamp":1536286969000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017216301147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["S0049017216301147"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2016.10.009","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The cost-effectiveness of HLA-B*5801 screening to guide initial urate-lowering therapy for gout in the United States","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2016.10.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}